Twist Bioscience Stock Price, News & Analysis

Twist Bioscience (NASDAQ: TWST) announced two licensing agreements through its Twist Biopharma division with Serotiny and Applied StemCell. The collaboration with Serotiny focuses on discovering novel Chimeric Antigen Receptors (CARs) for CAR T-Cell therapies, while the agreement with Applied StemCell involves using the TARGATT™ CHO Cell Technology for antibody therapeutics. Both partnerships aim to enhance Twist Biopharma's capabilities in developing novel therapies, potentially transforming treatment for challenging cancers.

Twist Bioscience Corporation (Nasdaq: TWST) has started shipping new synthetic RNA reference controls, including the SARS-CoV-2 variant strain B1.1.7. This strain's mutations may result in false negative COVID-19 test results due to some RT-PCR probes failing to detect the S gene. CEO Emily M. Leproust stated these controls help customers update testing protocols to reduce false negatives. Twist's controls support monitoring viral evolution and are used globally in various assays, demonstrating its commitment to improving health outcomes.

On January 11, 2021, ScanlanKemperBard (SKB), the General Partner of PW Venture Portland Limited Partnership, announced a significant lease agreement with Twist Bioscience Corporation (NASDAQ: TWST) at ParkWorks Industry Center in Wilsonville, Oregon. Twist has signed a lease for 110,000 square feet, marking the first lease executed since SKB acquired the property in April 2020. The deal is anticipated to enhance interest from life science and tech-manufacturing tenants as SKB implements extensive capital improvements to the facility.

Twist Bioscience (Nasdaq: TWST) has partnered with the CDC to provide customized SARS-CoV-2 Synthetic RNA Controls for the Flu SC2 Multiplex Assay, which tests for influenza and COVID-19. These positive controls enhance quality assurance for next-generation sequencing and RT-PCR assays. The CDC plans to utilize this assay across U.S. public health laboratories. Twist's CEO emphasized the optimization of these controls for stability at room temperature. This initiative reflects Twist's commitment to advancing public health through innovative solutions in bioscience.

Twist Bioscience Corporation (NASDAQ: TWST) announced that CEO Emily Leproust, Ph.D., will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11th at 5:20 p.m. ET. The presentation will be available via live webcast on the company's investor relations page. A replay will be archived for 30 days post-event. Twist Bioscience specializes in high-quality synthetic DNA production through a proprietary silicon platform. The company focuses on various applications including synthetic genes, next-generation sequencing tools, and biologics drug discovery.

Twist Bioscience Corporation (Nasdaq: TWST) announced plans to offer a new synthetic RNA control including the SARS-CoV-2 variant B1.1.7, which is 70% more transmissible according to preliminary UK data. This new synthetic control will support testing protocols affected by the variant's spike protein mutations. The controls are expected to be available by January 15, 2021, enhancing Twist's ongoing efforts in COVID-19 response. This follows the prior release of SARS-CoV-2 RNA controls for testing and development, establishing Twist as a key player in pandemic management.

Twist Bioscience (NASDAQ: TWST) announced plans to expand its manufacturing capabilities with a new "Factory of the Future" near Portland, Oregon. The 110,000-square-foot facility, expected to be operational in 2022, aims to create up to 400 jobs. CEO Emily M. Leproust emphasized that this facility will enhance production speed and support the growing synthetic biology and biopharma markets, facilitating aggressive growth. This strategic move aligns with Twist's mission to provide high-quality synthetic DNA through its innovative silicon platform.

Twist Bioscience Corporation (NASDAQ: TWST) has launched its Clonal-Ready Gene Fragments, enhancing its synthetic DNA offerings. This product aims to minimize the time and cost associated with screening for perfect clones, addressing a significant segment of the synthetic biology market. The Gene Fragments, produced via Twist's semiconductor-based platform, boast low error rates, which enhance efficiency for researchers needing smaller DNA amounts. This innovation positions Twist to better serve its customers and expand its market reach.

Twist Bioscience Corporation (NASDAQ: TWST) has successfully closed its public offering of 3,211,362 shares at $110.00 each, generating approximately $323.7 million in net proceeds. The offering included shares sold by both the company and certain selling stockholders. Twist plans to utilize these funds to enhance operational capacity, increase R&D investments, and expand its manufacturing capabilities for its synthetic DNA offerings. Additionally, a portion of the proceeds may be allocated towards acquiring complementary businesses.